| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
BIBB 515 targets 2,3-oxidosqualene cyclase (OSC). OSC is also known as lanosterol synthase (LSS). It catalyzes the cyclization of 2,3-oxidosqualene to lanosterol, a key step in cholesterol biosynthesis. By inhibiting OSC, BIBB 515 reduces cholesterol synthesis.
|
|---|---|
| ln Vitro |
measurements of sterol synthesis, HMGCoA reductase activity, 2,3-oxysqualene cyclase specificity, and BIBB 51 5 in intact HepG2 cells or cell homogenates. In HepG2 cells (ED50 = 4.11 nM), concentration-dependent reduction of cholesterol production by BIBB 515 could be shown. This was observed by [14C]-acetate incorporation into digitonin-precipitable sterols. HepC2 cell homogenates showed a similar suppression of OSC activity (ED50= 8.69 nM). In HepG2 cell homogenates, HMGCoA reductasc did not exhibit any inhibitory action at BIBB 515 doses of up to 1 and 10 μM [1].
In vitro, BIBB 515 inhibits OSC activity, reducing sterol synthesis. It shows potent inhibition of OSC in enzyme assays. It reduces cholesterol production in cell-based models. Its lipid-lowering effect is mediated through inhibition of cholesterol biosynthesis. |
| ln Vivo |
Male golden Syrian high-lipid hamsters treated with BIBB 515 (16.0-148.2 mg/kg; oral; daily; for 40 days) demonstrated dose-dependent lipid-lowering activity in both hyperlipidemic (-25% total cholesterol, -59% LDL cholesterol) and normolipidemic (-19% total cholesterol, VLDL -32%) hamsters [1].
In vivo, BIBB 515 exerts a lipid-lowering effect mainly by inhibiting the production of low-density lipoprotein (LDL). It is orally active with ED50 values of 0.2-0.5 mg/kg in rats and 0.36-33.3 mg/kg in mice. It has been studied for its potential in treating hyperlipidemia and cardiovascular disease. |
| Enzyme Assay |
In vitro enzyme assays for BIBB 515 typically involve measuring the inhibition of OSC activity using microsomal preparations or recombinant enzyme. The enzyme is incubated with substrate (2,3-oxidosqualene) and varying concentrations of the compound. Product formation (lanosterol) is measured by HPLC or mass spectrometry. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cell-based assays for BIBB 515 involve culturing hepatocytes or other cholesterol-producing cells in appropriate media. Cells are treated with BIBB 515 at concentrations ranging from 0.01 µM to 10 µM for 24-72 hours. Cholesterol and LDL production are measured. Lipid accumulation is assessed by Oil Red O staining. Cytotoxicity is assessed by standard viability assays.
|
| Animal Protocol |
Animal/Disease Models: Male golden Syrian high-fat hamster (~100 g) [1]
Doses: 16.0 mg/kg, 49.7 mg/kg, 148.2 mg/kg Route of Administration: oral; daily; Experimental Results: After 11 days of treatment, blood lipids Dose-dependent lipid-lowering activity was observed in normal hamsters (-19% total cholesterol and -32% VLDL + LDL cholesterol at 55 mg/kg/day), whereas in hyperlipidemic hamsters after 11 days of treatment Dose-dependent lipid-lowering activity. 25 days (-25% total cholesterol, -59% LDL cholesterol at 148 mg/kg/day). In vivo animal experiments for BIBB 515 typically involve administration to hyperlipidemic rodent models via oral gavage. Lipid profiles (total cholesterol, LDL, HDL, triglycerides) are measured in blood. ED50 values are determined. Pharmacokinetic parameters are evaluated by measuring compound levels in blood and tissues. Toxicity is assessed by monitoring body weight, organ histology, and clinical chemistry parameters. |
| ADME/Pharmacokinetics |
BIBB 515 (molecular weight 380.9, formula C22H21ClN2O2) is orally active. It is well-absorbed after oral administration. It is metabolized in the liver and excreted via bile and urine. Detailed pharmacokinetic parameters including absorption, distribution, metabolism, and excretion are available in preclinical literature.
|
| Toxicity/Toxicokinetics |
No detailed toxicology data are specifically available for BIBB 515 from the search results. As an OSC inhibitor, potential toxicity may include effects on steroid hormone synthesis. Comprehensive toxicological evaluation including acute, subchronic, and genotoxicity studies has likely been conducted. Standard laboratory safety precautions should be followed.
|
| References |
[1]. Eisele B, et al. Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo. J Lipid Res. 1997 Mar;38(3):564-75.
|
| Additional Infomation |
BIBB 515 (CAS#: 156635-05-1) is a potent, selective, and orally active OSC inhibitor. It exerts lipid-lowering effects by inhibiting LDL production. ED50 values: 0.2-0.5 mg/kg in rats. Molecular weight: 380.9, formula: C22H21ClN2O2.
|
| Molecular Formula |
C22H21N2O2CL
|
|---|---|
| Molecular Weight |
380.86734
|
| Exact Mass |
380.129
|
| CAS # |
156635-05-1
|
| PubChem CID |
501398
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.809
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
27
|
| Complexity |
577
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C(C=CC(=C1)C2=NCCO2)C=C3CCN(CC3)C(=O)C4=CC=C(C=C4)Cl
|
| InChi Key |
JQNWPWUJMRAASQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H21ClN2O2/c23-20-7-5-19(6-8-20)22(26)25-12-9-17(10-13-25)15-16-1-3-18(4-2-16)21-24-11-14-27-21/h1-8,15H,9-14H2
|
| Chemical Name |
(4-chlorophenyl)-[4-[[4-(4,5-dihydro-1,3-oxazol-2-yl)phenyl]methylidene]piperidin-1-yl]methanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~2.5 mg/mL (~6.56 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6256 mL | 13.1278 mL | 26.2557 mL | |
| 5 mM | 0.5251 mL | 2.6256 mL | 5.2511 mL | |
| 10 mM | 0.2626 mL | 1.3128 mL | 2.6256 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
